Medytox Adds Manufacturing Facility E at Osong Plant 3 for 'Coretox'... Accelerating Market Expansion

Following Newlux, Coretox Production Begins
at Osong Plant 3 Building E

Biopharmaceutical company Medytox announced on the 24th that it has added Building E of Osong Plant 3 as a new manufacturing site for 'Coretox,' a non-animal-derived botulinum toxin preparation purified to contain only the neurotoxin with a molecular weight of 150kDa, which is the key active ingredient responsible for its pharmacological effect.

Coretox, developed by Medytox in 2016, is characterized by isolating only the 150kDa neurotoxin, the active ingredient, by removing non-toxic proteins unrelated to efficacy, unlike conventional 900kDa botulinum toxin preparations. Additionally, animal-derived components were excluded during manufacturing processes such as strain cultivation and bulk production. Instead of human serum albumin (HSA), non-animal-derived excipients like polysorbate 20 and L-methionine were used to further reduce the risk of additional infections.

Initially, Coretox was produced only at Ochang Plant 1. In November 2021, Medytox received approval from the Ministry of Food and Drug Safety (MFDS) to use Building B of Plant 3 as a manufacturing site and began mass production. With the addition of Building E, which has more than three times the production capacity of Building B, production can now be expanded further. Medytox plans to leverage this capacity expansion to increase the domestic market share of its flagship product Coretox and prepare for overseas expansion.

A Medytox representative stated, "With the addition of this manufacturing site, the position of Coretox, which has a mass production system and differentiated product quality, will be further solidified," adding, "This also enables proactive response to increased demand from future global expansion."

Meanwhile, Building E at Osong Plant 3, newly established last year, began full-scale operation following the addition of a manufacturing site for the next-generation botulinum toxin preparation 'Newlux' by its affiliate Newmeco, establishing itself as a core production base for Medytox.

This content was produced with the assistance of AI translation services.